Dizal Stock Rises After FDA Approval for Rare Lung Cancer Treatment

Shares of Dizal Pharmaceutical soared this week after the U.S. Food and Drug Administration (FDA) approved its innovative treatment for a rare form of lung cancer. The approval of golidocitinib, marketed as Gavreto, marks a breakthrough for patients with EGFR exon 20 insertion mutations, a subtype of non-small cell lung cancer (NSCLC) that has long lacked effective treatment options. The news sent Dizal Stock up sharply, drawing fresh attention from biotech investors worldwide.